Literature DB >> 25256714

Osteoprotegerin expressed by osteoclasts: an autoregulator of osteoclastogenesis.

J H Kang1, H M Ko2, J S Moon1, H I Yoo1, J Y Jung1, M S Kim1, J T Koh1, W J Kim1, S H Kim3.   

Abstract

Osteoprotegerin (OPG) is secreted by stromal and osteoblastic lineage cells and inhibits osteoclastogenesis by preventing the interaction of receptor activator of nuclear factor-κB ligand (RANKL) with receptor activator of nuclear factor-κB (RANK). In this study, the expression of OPG in osteoclasts themselves and its biological functions during osteoclastogenesis were investigated for the first time. OPG expression in vivo in the developing rat maxilla was examined by immunofluorescence analysis. OPG expression in osteoclasts during in vitro osteoclastogenesis was determined by reverse-transcription polymerase chain-reaction (RT-PCR), Western blot, and immunofluorescence staining. We determined the function of OPG produced by osteoclasts during osteoclastogenesis by silencing the OPG gene. The effects of OPG on bone-resorbing activity and apoptosis of mature osteoclasts were examined by the assay of resorptive pit formation on calcium-phosphate-coated plate and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining, respectively. In the immunofluorescence findings, strong immunoreactivities were unexpectedly seen in multinucleated tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts around the growing and erupting tooth germs in the rat alveolar bone. In vitro, OPG expression was significantly increased during the differentiation of osteoclasts from mouse bone-marrow-derived cells treated with a combination of macrophage colony-stimulating factor (M-CSF) and RANKL. Interestingly, it was found that OPG small interfering (si)RNA treatment during osteoclastogenesis enhanced the sizes of osteoclasts, but attenuated their bone-resorbing activity. Also, the increased chromosomal DNA fragmentation and caspase-3 activity in the late phase of osteoclastogenesis were found to be decreased by treatment with OPG siRNA. Furthermore, effects of OPG siRNA treatment on osteoclastogenesis and bone-resorbing activity were recovered by the treatment of exogenous OPG. These results suggest that OPG, expressed by the osteoclasts themselves, may play an auto-regulatory role in the late phase of osteoclastogenesis through the induction of apoptosis. © International & American Associations for Dental Research.

Entities:  

Keywords:  M-CSF; OPG; RANKL; apoptosis; autoregulation; resorption

Mesh:

Substances:

Year:  2014        PMID: 25256714      PMCID: PMC4293774          DOI: 10.1177/0022034514552677

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  36 in total

1.  Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor.

Authors:  A Truneh; S Sharma; C Silverman; S Khandekar; M P Reddy; K C Deen; M M McLaughlin; S M Srinivasula; G P Livi; L A Marshall; E S Alnemri; W V Williams; M L Doyle
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

Review 2.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

3.  Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP).

Authors:  Ya-Hui Chiu; Kofi A Mensah; Edward M Schwarz; Yawen Ju; Masahiko Takahata; Changyong Feng; Loralee A McMahon; David G Hicks; Ben Panepento; Peter C Keng; Christopher T Ritchlin
Journal:  J Bone Miner Res       Date:  2012-01       Impact factor: 6.741

4.  Osteoprotegerin protects endothelial cells against apoptotic cell death induced by Porphyromonas gingivalis cysteine proteinases.

Authors:  Michiyo Kobayashi-Sakamoto; Kimiharu Hirose; Makoto Nishikata; Emiko Isogai; Itsuo Chiba
Journal:  FEMS Microbiol Lett       Date:  2006-09-19       Impact factor: 2.742

Review 5.  RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function.

Authors:  Michael Schoppet; Klaus T Preissner; Lorenz C Hofbauer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-04-01       Impact factor: 8.311

6.  Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.

Authors:  N Udagawa; N Takahashi; H Yasuda; A Mizuno; K Itoh; Y Ueno; T Shinki; M T Gillespie; T J Martin; K Higashio; T Suda
Journal:  Endocrinology       Date:  2000-09       Impact factor: 4.736

7.  Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.

Authors:  Claire M Shipman; Peter I Croucher
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

8.  Negative feedback Inhibition of NFATc1 by DYRK1A regulates bone homeostasis.

Authors:  Youngkyun Lee; Jeongim Ha; Hyung Joon Kim; Yeun-Soo Kim; Eun-Ju Chang; Woo-Joo Song; Hong-Hee Kim
Journal:  J Biol Chem       Date:  2009-10-02       Impact factor: 5.157

9.  Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone.

Authors:  I Nakamura; M F Pilkington; P T Lakkakorpi; L Lipfert; S M Sims; S J Dixon; G A Rodan; L T Duong
Journal:  J Cell Sci       Date:  1999-11       Impact factor: 5.285

10.  Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis.

Authors:  Denis Lane; Isabelle Matte; Claude Laplante; Perrine Garde-Granger; Claudine Rancourt; Alain Piché
Journal:  J Ovarian Res       Date:  2013-11-23       Impact factor: 4.234

View more
  12 in total

Review 1.  The role of bone biopsy for the diagnosis of renal osteodystrophy: a short overview and future perspectives.

Authors:  Catarina Carvalho; Catarina Moniz Alves; João Miguel Frazão
Journal:  J Nephrol       Date:  2016-07-29       Impact factor: 3.902

2.  Inhibition of osteoclast differentiation and collagen antibody-induced arthritis by CTHRC1.

Authors:  Yong-Ri Jin; J Patrizia Stohn; Qiaozeng Wang; Kenichi Nagano; Roland Baron; Mary L Bouxsein; Clifford J Rosen; Vyacheslav A Adarichev; Volkhard Lindner
Journal:  Bone       Date:  2017-01-21       Impact factor: 4.398

3.  Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).

Authors:  Neelima Vidula; Christina Yau; Jiali Li; Laura J Esserman; Hope S Rugo
Journal:  Breast Cancer Res Treat       Date:  2017-06-02       Impact factor: 4.872

4.  Malva sylvestris Inhibits Inflammatory Response in Oral Human Cells. An In Vitro Infection Model.

Authors:  Bruna Benso; Pedro Luiz Rosalen; Severino Matias Alencar; Ramiro Mendonça Murata
Journal:  PLoS One       Date:  2015-10-19       Impact factor: 3.240

5.  Effects of Osteogenic-Conditioned Medium from Human Periosteum-Derived Cells on Osteoclast Differentiation.

Authors:  Hyun-Chang Park; Young-Bum Son; Sung-Lim Lee; Gyu-Jin Rho; Young-Hoon Kang; Bong-Wook Park; Sung-Hoon Byun; Sun-Chul Hwang; In-Ae Cho; Yeong-Cheol Cho; Iel-Yong Sung; Dong Kyun Woo; June-Ho Byun
Journal:  Int J Med Sci       Date:  2017-11-02       Impact factor: 3.738

6.  Deciphering the Relationship between Obesity and Various Diseases from a Network Perspective.

Authors:  Lei Chen; Yu-Hang Zhang; JiaRui Li; ShaoPeng Wang; YunHua Zhang; Tao Huang; Yu-Dong Cai
Journal:  Genes (Basel)       Date:  2017-12-18       Impact factor: 4.096

7.  An in vitro 3D bone metastasis model by using a human bone tissue culture and human sex-related cancer cells.

Authors:  Francesca Salamanna; Veronica Borsari; Silvia Brogini; Gianluca Giavaresi; Annapaola Parrilli; Simona Cepollaro; Matteo Cadossi; Lucia Martini; Antonio Mazzotti; Milena Fini
Journal:  Oncotarget       Date:  2016-11-22

8.  Polymethyl methacrylate does not adversely affect the osteogenic potential of human adipose stem cells or primary osteoblasts.

Authors:  Angela P Bastidas-Coral; Astrid D Bakker; Cornelis J Kleverlaan; Jolanda M A Hogervorst; Jenneke Klein-Nulend; Tymour Forouzanfar
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2019-10-24       Impact factor: 3.368

9.  Suppression of AMP-activated protein kinase reverses osteoprotegerin-induced inhibition of osteoclast differentiation by reducing autophagy.

Authors:  Xishuai Tong; Chuang Zhang; Dong Wang; Ruilong Song; Yonggang Ma; Ying Cao; Hongyan Zhao; Jianchun Bian; Jianhong Gu; Zongping Liu
Journal:  Cell Prolif       Date:  2019-11-07       Impact factor: 6.831

10.  Nanovibrational stimulation inhibits osteoclastogenesis and enhances osteogenesis in co-cultures.

Authors:  John W Kennedy; P Monica Tsimbouri; Paul Campsie; Shatakshi Sood; Peter G Childs; Stuart Reid; Peter S Young; Dominic R M Meek; Carl S Goodyear; Matthew J Dalby
Journal:  Sci Rep       Date:  2021-11-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.